Subscribe
istock-ciphotos-istockphoto-com665048016-1-
CIPhotos / iStockphoto.com
31 January 2019Americas

Celgene signs $1bn deal to develop blood cancer therapy

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent